In diabetic patients plasma levels of pancreatic polypeptide (PP) increased four fold after intramuscular injection of secretin (50CHRU, Eisai Co.) in spite of the lack of response of plasma insulin, plasma glucagon and blood glucose levels. In control subjects, PP levels did not change significantly after secretin injection.
Secretin has been isolated as an intestinal polypeptide with27amino
acid residues (Mutt and Jorpes, 1965) . The fact that insulin secretion is enhanced by the injection of secretin (Dupre, 1964; Deckert, 1968; Dupre et al., Lerner and Porte1972; Shima and Tarui, 1974) has promoted investigation of the interaction between intestinal hormones and pancreatic islet cells. The present study was undertaken to determine whether in diabetic patients secretin stimulates the release of pancreatic polypeptide (pp), a newly recognized hormone with a6amino acid sequence (Lin et al., 1977) .
Subjects and Methods
Ten diabetic patients aged from28to73years (mean48.8) including two patients with juvenile onset diabetes and ten healthy subjects aged from26to 43years (mean35.5) were studied. Table. 1.
Discussion
Although secretin stimulates or potentiates insulin release in pharmacologic experiments (Dupre, 1964; Deckert, 1968; upre et al., 1969; Lerner and Parte, 1972) , a physiological role of secretin in insulin secretion has not been recognized (Boyns et al., 1967; Buchanan et al., 1968 ). The present study shows that secretin has no acute effect on the release of insulin and glucagon. Recently, Adrian et al.(1978) reported that secretin (1mol/l) clearly enhances insulin levels in dogs at the8.3 mol/l glucose concentration.
The effect was not recognized at lower glucose concentration. The intravenous injection of ten units of secretin during glucose infusion has also been found to cause a rise in plasma insulin in humans (Shima and Tarui1974 It is surprising that the amount of pancreatic polypeptide increased remarkably after an injection of secretin in diadetic patients. Gut hormones, especially gastrin, GIP, VIP stimulate release of pancreatic polypeptide (Adrian et al., 1978) , but an acute stimulatory effect of secretin has never been found. It could not be ruled out completely that the secretin-prearation used in the present study might be contaminated with GIP, VIP and other peptides. However, as trace amounts of these gut hormones less than0.01%) seldom, if any, increased the release of insulin and glucagon, the stimulation of PP secretion in diabetic patients is probably mediated by secretin itself. From the viewpoint on the enteroinsular axis, it is important that there is an interaction of secretin with pancreatic polypeptide in diabetic patients. Because pancreatic polypeptide inhibits the output of bicarbonate and amylase into pancreatic juice (Taylor et al., 1979) , the remarkable response of pancreatic polypeptide to secretin possibly disturbs the function of the exocrine pancreas in diabetic patients.
Pancreatic polypeptide is released from the pancreatic islet cells which have paracrine effects (Weir et al., 1979) . However, pancreatic polypeptide itself has no acute effect on the A, B and D cells (Ipp et al., 1978) . In the postprandial period, the pancreatic polypeptide is continuously released to sustain high blood levels (Floyd et al., 1978; Taylor et al., 1979) . In adult onset diabetes, postprandial levels of pancreatic polypeptide were significantly higher than normal controls (Ishida et al., 1979) . Therefore, it is possible that in diabetic patients the response of pancreatic polypeptide to gut hormones including secretin, gastrin, GIP and VIP is remarkably increased. Since it is unknown why and how pancreatic polypeptide is increased after intramuscular injection of secretin in diabetic patients, further study is necessary to obtain an understanding of the modulation of pancreatic polypeptide secretion by gut hor-mones in diabetic patients.
